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Probiotics and vitamin C for the prevention of respiratory
tract infections in children attending preschool: a randomised
controlled pilot study
I Garaiova1,7, J Muchová2,7, Z Nagyová3, D Wang4, JV Li5,6, Z Országhová2, DR Michael1, SF Plummer1 and Z Ďuračková2
BACKGROUND: This pilot study investigates the efﬁcacy of a probiotic consortium (Lab4) in combination with vitamin C on the
prevention of respiratory tract infections in children attending preschool facilities.
SUBJECTS/METHODS: In a double-blind, randomised, placebo-controlled pilot study with children aged 3–6 years, 57 received
1.25 × 1010 colony-forming units of Lactobacillus acidophilus CUL21 (NCIMB 30156), Lactobacillus acidophilus CUL60 (NCIMB 30157),
Biﬁdobacterium biﬁdum CUL20 (NCIMB 30153) and Biﬁdobacterium animalis subsp. lactis CUL34 (NCIMB 30172) plus 50mg vitamin C
or a placebo daily for 6 months.
RESULTS: Signiﬁcant reductions in the incidence rate of upper respiratory tract infection (URTI; 33%, P= 0.002), the number of days
with URTI symptoms (mean difference: − 21.0, 95% conﬁdence interval (CI):− 35.9, − 6.0, P= 0.006) and the incidence rate of
absence from preschool (30%, P= 0.007) were observed in the active group compared with the placebo. The number of days of use
of antibiotics, painkillers, cough medicine or nasal sprays was lower in the active group and reached signiﬁcance for use of cough
medicine (mean difference: − 6.6, 95% CI: − 12.9, − 0.3, P= 0.040). No signiﬁcant differences were observed in the incidence rate
ratio or duration of lower respiratory tract infection or in the levels of plasma cytokines, salivary immunoglobulin A or urinary
metabolites.
CONCLUSIONS: Supplementation with a probiotic/vitamin C combination may be beneﬁcial in the prevention and management
of URTIs.
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INTRODUCTION
Respiratory tract infection (RTI) in children presents a considerable
health-care burden involving not only the cost of direct medical
care but also that incurred due to parental absence from work.1
Children attending preschool are three times more likely to suffer
an infection than those staying at home due to high transmission
rates within such facilities.2 RTIs can occur in the upper or lower
respiratory tract affecting the sinuses, throat, airways or lungs.
Antibiotics are administered for bacterial infections, but their
inadvertent use for viral infections is ineffective and can
contribute to antibiotic overuse and antibiotic resistance.3
Alternative strategies for the prevention of RTI in children
attending preschool are needed.4
Evidence suggests that supplementation with probiotics may
prevent upper respiratory tract infections (URTIs).5 Probiotics are
deﬁned as ‘live microorganisms that when administered in
adequate amounts confer a health beneﬁt on the host’.6 Some
studies using probiotics alone for children attending preschool
facilities have shown signiﬁcant reductions in incidence and/or
duration of URTIs7–11 while others observed little or no effect.12,13
Meta-analysis of the results from supplementation with vitamin C
also suggests a beneﬁcial effect on the duration of common cold
symptoms in children.14
Administration of Lactobacillus plantarum NCIMB 8826 or
Lactobacillus reuteri F275 prevented severe RTI in healthy mice
by reducing pro-inﬂammatory cytokine expression at the respira-
tory mucosa,15 and an ‘anti-inﬂammatory priming’ of immunity
has been observed in peripheral blood mononuclear cells
extracted from healthy humans supplemented with the Lab4
probiotic consortium.16 Vitamin C has also been shown to hinder
the pro-inﬂammatory cytokine response in monocytes and
lymphocytes extracted from healthy adults,17 but to date, no
studies have examined the effect of a probiotic and vitamin C
combination on RTI in preschool children. The objective of this
study was to investigate the impact of a probiotic consortium in
combination with vitamin C on both the incidence and duration of
RTIs and assess any associated immunological and metabolic
changes in children.
MATERIALS AND METHODS
Participants
Sixty-nine healthy children (3–6 years) attending preschool in Slovakia
were recruited into the study. Written informed consent was obtained
from parents or legal guardians prior to participation in the study. Children
were excluded if they were taking medication or immunostimulatory
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products or any form of probiotic prior to or at the time of enrolment or if
sensitive to xylitol/sorbitol. None of the children received the ﬂu vaccine
during the study period.
Study design and intervention
A double-blinded, randomised, placebo-controlled study was conducted.
The protocol was approved by the Ethical Committee of the Department of
Health Care and Human Pharmacy, Trnava, Slovakia (16/09/2010) and
registered with Current Controlled Trials (ISRCTN28722693). During the
6-month intervention study period, children received daily either one
chewable tablet containing the Lab4 probiotic consortium comprising two
strains of Lactobacillus acidophilus CUL21 (NCIMB 30156) and CUL60 (NCIMB
30157), Biﬁdobacterium biﬁdum CUL20 (NCIMB 30153) and Biﬁdobacterium
animalis subsp. lactis CUL34 (NCIMB 30172) at a total of 1.25 × 1010 colony-
forming units (Lactobacillus sp. 1 × 1010 and Biﬁdobacterium sp. 0.25× 1010)
and 50mg vitamin C on a base of xylitol or an identical looking placebo
tablet containing xylitol (Cultech Ltd, Port Talbot, UK). Compliance was
assessed by monitoring the amount of tablets returned.
Data collection
The children were examined by a paediatric physician and background
information, including the history of allergy, was recorded. Body weight
and height were measured using a digital weighing and measuring station
with automatic body mass index calculation (kg/m2, SECA 764, SECA
Deutschland, Hamburg, Germany). Twelve-hour overnight fasting venous
blood samples were collected into EDTA-vacutainer tubes, and the plasma
was extracted by centrifugation (1200 g, 10 min) before storage at − 80 °C.
Urine samples were collected from the ﬁrst morning urination and stored
at − 80 °C prior to 1H nuclear magnetic resonance (NMR) analysis. Before
saliva collection, children rinsed out their mouths with cold water, and
saliva was collected in plastic tubes and stored at − 20 °C. Parents/
guardians completed weekly symptom diaries monitoring temperature,
runny nose, sore throat, cough, chest wheezes, earache, diarrhoea,
vomiting, stomach aches, absence from preschool, prescriptions of
antibiotics, physician visits, hospitalisation and any medication taken
during the intervention period. At the start and end of the study, they
completed a dietician-designed diet habit and physical activity pattern
questionnaire consisting of 3 questions on meal and drink patterns, 12
questions on intake of various foods and 3 questions relating to physical
activities. The questionnaires were assessed using a scoring system, and
summary scores at baseline and upon completion of the study were
compared.
During the intervention period, children were examined by a paediatric
physician at prescheduled 2-, 4- and 6-month appointments or during
unscheduled visits resulting from URTI, LRTI or any other illness. At
6 months, blood, urine and saliva were collected. Not all children provided
a saliva or blood sample on the collection days thereby reducing the active
and placebo group size.
Measurement of plasma cytokine levels
Quantiﬁcation of interferon-γ (IFN-γ), interleukin (IL)-10, IL-12p70, IL-13,
IL-1β, IL-2, IL-4, IL-5, IL-8 and tumour necrosis factor-α (TNF-α) was
conducted using a MULTI-SPOT electrochemiluminescence array (MSD
technology) in accordance with the manufacturer’s protocol (CBS, Cardiff
University, Cardiff, UK).
Measurement of total salivary immunoglobulin A (IgA)
Saliva samples were centrifuged at 800 g for 15 min, and IgA levels were
assayed by enzyme-linked immunosorbant assay (E80-102, Bethyl Labora-
tories, Montgomery, AL, USA).
1H NMR spectroscopic analysis of urinary samples
Urine samples were thawed at room temperature, vortexed for 10 s and
centrifuged at 10 000 g for 10 min, and the supernatant was transferred
into a 96-well plate and using a robotic system (Bruker, Rheinstetten,
Germany). In all, 540 μl of urinary sample was mixed with 60 μl
of 1.5 M potassium phosphate buffer in D2O, pH=7.4, 0.1%
3-(trimethylsilyl)-[2,2,3,3-2H4] propionic acid sodium salt (TSP) and 2mM
sodium azide and transferred into an NMR tube. 1H NMR spectra were
acquired using a Bruker 600MHz spectrometer (BrukerGermany) at the
operating 1H frequency of 600.13 MHz at a temperature of 300 K.
A standard NMR pulse sequence (recycle delay-90°-t1-90°-tm-90°-acquisition)
provided a standard one-dimensional 1H NMR spectral data (t1 was 3ms
and tm (mixing time) was 10ms). The water peak suppression was achieved
using selective irradiation during a recycle delay of 4 s and tm. A 90-degree
pulse was adjusted to 10 μs. A total of 32 scans were collected into 64 k
data points with a spectral width of 20 p.p.m.
PLACEBO GROUP
(n=35)
ACTIVE GROUP
(n=34)
Withdrawn from study
Adverse events (n=1)
Unknown reason (n=1)
INTENTION TO TREAT ANALYSIS
(n=33)
INTENTION TO TREAT ANALYSIS
(n=33)
Drop-outs
Adverse events (n=1)
Excluded
Non-authorised treatment (n=3)
PER PROTOCOL ANALYSIS
(n=29)
PER PROTOCOL ANALYSIS
(n=28)
Withdrawn from study
Unknown reason (n=1)
69 CHILDREN RANDOMISED
Drop-Outs
Unrelated disease (n=1)
Unknown reason (n=1)
Excluded
Non-authorised treatment (n=3)
Figure 1. Participant’s ﬂow chart.
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Randomisation
Eligible subjects were allocated in a 1:1 ratio to the two arms of the study
according to a computer-generated random sequence using block
randomisation with a block-size of four. The randomisation was performed
by the study statistician, who had no contact with the participants.
Participants were enrolled and assigned sequentially to interventions by the
paediatric physician. The allocation sequence was not available to any
member of the research team until databases had been completed and
locked.
End point measures
The primary end point measures were the incidence and duration of URTI
and lower respiratory tract infection (LRTI), absence from preschool and
number of visits to the paediatric centre due to RTI. URTI symptoms
included sneezing, sore throat, cough, runny and blocked nose. Each
distinct episode was the time period (in days) covering the continuous
display of symptoms, separated from another episode by a minimum of
24 h. LRTI was conﬁrmed by a paediatric physician, and LRTI duration was
the number of days between the physician conﬁrmed onset and absence
of symptoms. Secondary end points were changes in plasma cytokines,
salivary IgA and urine metabolites. Parent-reported measures included
diarrhoea (⩾3 loose stools in a 24-h period), vomiting and stomach aches.
Data management and analysis
As a pilot study there was no a formal sample size calculation. For the
primary end point analysis, incidence rate ratio (number of episodes
divided by the number of days in the study) and mean difference in the
duration of URTIs and LRTIs, absence from preschool and number of visits
to paediatric centre for RTIs during the intervention period with 95%
conﬁdence intervals (CIs) were calculated using a generalised linear model
(GLM) that included treatment as a single predictor. The secondary
immunological end points were analysed similarly. For the GLM analysis of
a continuous end point such as duration of URTI and LRTI, normal
distribution and identity link functions were used. For the GLM analysis of
recurrence of events (such as the number of episodes of URTI symptoms),
Poisson distribution and log link functions were used. Post-hoc covariate-
adjusted analyses within the GLM framework were performed on the
primary end points with treatment as study variable and centre, age,
gender and body mass index as covariates. Subgroup analysis was
performed by gender. Continuous variables were summarised using the
number of observations, mean (s.d.), whereas categorical variables were
summarised by the number and percentage of events.
Analysis of study end points was performed in per protocol analysis (PP)
and a modiﬁed intention-to-treat (ITT) population excluding the partici-
pants who withdrew shortly after randomisation. Dietary habit and
physical exercise questionnaire data analysis was performed using the
GLM model, with treatment as study variable and baseline measurement
as covariate. Data analyses were performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA).
1H NMR data analysis
Automatic phasing, baseline correction and reference to TSP signal at δ1H
0.00 were performed on the 1H NMR urinary spectra. The processed NMR
spectral data (δ1H 0.25–10) were imported to MATLAB (R2012a, 7.14.0.739,
MathWorks) and digitised into 20 k data points with a resolution of
0.0005 p.p.m. using a MATLAB script developed within the Section of
Computational and Systems Medicine. The water peak region (δ1H 4.7–4.9)
was removed owing to its disordered peak shape caused by water
suppression. In addition, variations of the intensity of urea signal (δ1H
5.4–6.1) can be caused by chemical exchange with the solvent; hence the
region was also removed. Probabilistic quotient normalisation was
performed on the remaining spectral data in order to account for dilution
of complex biological mixtures. Principal component analysis and
orthogonal partial least squares discriminant analysis were carried out on
the unit variance-scaled data in THE SIMCA (P+13.0) and MATLAB software.
Orthogonal partial least squares regression analyses were performed to
correlate metabolic data with cytokine measurement.
RESULTS
Enrolment and baseline characteristics
Sixty-nine children were enrolled between October 2010 and
March 2011; 35 into the placebo group and 34 into active. Three
children did not provide any records and withdrew from the
study. Nine children were excluded from the PP analysis; six due to
non-authorised treatment usage and three due to non-completion
of the follow-up period (Figure 1). As can be seen in Table 1, the
baseline data for both groups appears comparable. The cohort
consists of 16 girls and 17 boys per group with the mean age of 5
years. In all, 12% of children in the placebo group and 6% in active
group had atopic diseases.
Primary end points
There was a signiﬁcant reduction in the duration of total URTI
symptoms (days) in the active group compared with the placebo
(PP analysis; mean difference: − 21.0, 95% CI:− 35.9, − 6.0,
P= 0.006, ITT analysis; mean difference: − 17.9, 95% CI:− 31.6,
− 4.2, P= 0.011; Table 2). The incidence rate of URTI symptoms in
the active group was 0.0196 compared with 0.0293 in the placebo
group (33% reduction, 95% CI in reduction: 14%, − 48%, P= 0.002,
PP analysis; Table 3). A similar result was seen when an ITT analysis
was performed.
In all, 35.7% of children in the active group experienced ⩾ 3
different URTI symptoms per URTI episode compared with 51.7%
of children in the placebo group (risk difference: 16%, 95% CI:
− 9.4%, 41.4%, P= 0.217, PP analysis). There were no signiﬁcant
differences in the duration or incidence rate ratio of LRTIs
(Table 4).
The incidence rate of absence from preschool in the active
group was 0.0198; 30% lower than in the placebo group (0.0282,
P= 0.007, PP analysis), and there was a trend towards signiﬁcance
for the number of days absent from preschool and the number of
paediatric physician visits due to URTI symptoms (P= 0.070 and
P= 0.082, respectively, Table 2, PP analysis) in the active group
compared with placebo group. No signiﬁcant differences in the
number of days absent from preschool or physician visits due to
LRTI were observed, and there was no hospitalisation due to RTIs
Table 1. Baseline demographics
Placebo
(N= 33)
Active
(N= 33)
All
(N= 66)
Gender (n)
Girls 16 16 32
Boys 17 17 34
Age (years)a 5.0 (0.7) 4.9 (0.8) 5.0 (0.9)
Girls 4.9 (0.8) 4.8 (0.9) 4.8 (0.8)
Boys 5.2 (0.6) 5.0 (0.8) 5.1 (0.7)
BMI (kg/m2)a 15.6 (2.5) 15.5 (2.2) 15.5 (2.3)
Girls 15.3 (2.0) 15.8 (2.4) 15.5 (2.2)
Boys 15.9 (2.9) 15.2 (2.0) 15.5 (2.5)
Centre, n (%)
Centre 1 21 (63.6) 21 (63.6) 42 (63.6)
Centre 2 6 (18.2) 6 (18.2) 12 (18.2)
Centre 3 6 (18.2) 6 (18.2) 12 (18.2)
Eczema, n (%) 5 (15.2) 2 (6.1) 7 (10.6)
Atopic disease,b n (%) 4 (12.1) 2 (6.1) 6 (9.1)
Food allergy, n (%) 3 (9.1) 0 (0) 3 (4.5)
Coeliac disease, n (%) 0 (0) 1 (3.0) 1 (1.5)
Abbreviation: BMI, Body Mass Index. aData are presented as mean (s.d.),
intention to treat analysis. bAllergic rhinitis, atopic eczema or asthma.
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during the course of the study. The results from post-hoc
covariate-adjusted analysis are similar to those from unadjusted
analysis (Supplementary Tables S3–S5).
Secondary end points
There were no signiﬁcant differences in plasma cytokine levels
between groups, but there were signiﬁcant reductions in IL-12p70,
IL-13, IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10 and TNF-α between baseline
and 6 months (data not shown). IFN-γ levels and IL-2/IL-5 were
signiﬁcantly reduced in the active group after 6 months (IFN-γ;
P= 0.035, mean difference: − 3.1; 95% CI: − 6.0, − 0.2 and IL-2/IL-5;
P= 0.023; mean difference: − 0.2; 95% CI: − 0.5, − 0.04, PP analysis)
but not for the placebo group. There were no signiﬁcant
differences in the IgA levels between the groups (P= 0.438; mean
difference: 31.2; 95% CI: − 50.3, 112.8, PP analysis).
The principal component analysis score plots of the urine
metabolic proﬁles, including outliers, are presented in Figure 2,
but no signiﬁcant changes were observed with or without outliers.
Orthogonal partial least squares regression analyses were used to
statistically correlate metabolic proﬁles with measured cytokine
levels, but no signiﬁcant correlation was obtained. A set of
representative 1H NMR spectra are shown in Supplementary
Figure S1.
Additional parameters, use of antibiotics and other medications
There were no signiﬁcant differences in either the incidence rate or
the number of days with earache, chest wheeze, temperature
437 °C, stomach ache, vomiting or diarrhoea between the groups.
The observed number of days of antibiotic, painkiller, cough
medicine, nasal spray/drop or antihistamine usage was lower in the
active group compared with the placebo and was signiﬁcant for
cough medicine usage (mean difference: − 6.6, 95% CI: − 12.9, − 0.3,
P=0.040, PP analysis). Seven of the 29 children (24.1%) received
oral antibiotics in the placebo group compared with 4 of the 28
children (14.3%) in the active group (P=0.356, PP analysis). There
was no hospitalisation due to RTIs during the course of the study.
Subgroup analysis on the basis of gender
A signiﬁcant reduction in number of days with URTI symptoms
was observed in boys (P= 0.024; mean difference: − 25.6; 95%
Table 2. Duration of URTI symptoms, absence and paediatric physician visits
PP analysis ITT analysis
Placebo (N= 29) Active (N= 28) Placebo (N= 33) Active (N= 33)
URTI symptoms
Mean (s.d.), days 43.1 (35.4) 22.1 (21.0) 41.5 (34.5) 23.5 (21.8)
Mean difference (95% CI) − 21.0 (−35.9,− 6.0) − 17.9 (−31.6,− 4.2)
P-value 0.006 0.011
Individual URTI symptoms
Sneezing
Mean (s.d.), days 9.6 (14.8) 2.3 (4.0) 9.0 (14.1) 3.8 (8.6)
Mean difference (95% CI) − 7.4 (−12.9, − 1.8) − 5.1 (−10.7, 0.4)
P-value 0.010 0.069
Cough
Mean (s.d.), days 23.5 (20.3) 11.9 (10.1) 22.3 (19.8) 14.3 (14.4)
Mean difference (95% CI) − 11.6 (−19.8, − 3.4) − 7.9 (−16.2, 0.3)
P-value 0.006 0.058
Runny nose
Mean (s.d.), days 21.4 (25.5) 11.5 (15.6) 19.8 (24.6) 12.3 (15.8)
Mean difference (95% CI) − 10.0 (−20.8, 0.9) − 7.4 (−17.2, 2.4)
P-value 0.072 0.138
Blocked nose
Mean (s.d.), days 9.8 (23.8) 4.9 (7.8) 10.4 (23.0) 5.4 (8.4)
Mean difference (95% CI) − 5.0 (−14.1, 4.1) − 5.0 (−13.2, 3.2)
P-value 0.285 0.230
Sore throat
Mean (s.d.), days 2.8 (4.2) 1.9 (2.7) 3.2 (4.3) 1.8 (2.6)
Mean difference (95% CI) − 0.9 (−2.7, 0.9) − 1.4 (−3.1, 0.3)
P-value 0.332 0.010
Absence, physician visits
Absence from preschool due to URTI
Mean (s.d.), days 14.2 (18.4) 7.5 (8.0) 13.9 (17.7) 7.7 (8.6)
Mean difference (95% CI) − 6.7 (−14.0, 0.5) − 6.1 (−12.8, 0.5)
P-value 0.070 0.069
Number of physician visit due to URTI
Mean (s.d.) 2.9 (3.1) 1.6 (2.2) 2.8 (3.0) 1.8 (2.4)
Mean difference (95% CI) − 1.2 (−2.6, 0.2) − 0.9 (−2.2, 0.4)
P-value 0.082 0.164
Abbreviations: CI, conﬁdence interval; ITT, intention to treat; PP, per protocol; URTI, upper respiratory tract infection.
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CI: − 47.7, − 3.4, PP analysis) compared with the girl groups
(P= 0.084; mean difference: − 17.6; 95% CI: − 37.5, 2.4, PP analysis)
(Supplementary Table S1). No signiﬁcant differences in the
duration or incidence of LRTI symptoms were observed between
genders (Supplementary Table S2).
Signiﬁcant decreases or trends toward signiﬁcance were observed
in IL-12p70 (P=0.060, 95% CI: − 0.6, 0.0), IL-12p70/IL-10 (P=0.025,
95% CI: −0.3, − 0.02), IL-12p70/IL-5 (P=0.032, 95% CI: − 2.0, − 0.1) and
IL-2/IL-10 (P=0.025, 95% CI: −0.3, − 0.02) for boys in the active group
compared with the placebo (PP analysis). No signiﬁcant changes in
the immune parameters were observed in the girls group.
Compliance, dietary assessment, adverse events
Mean compliance to the product for the whole group was 90.8%.
No signiﬁcant differences in dietary habits and physical activity
patterns were observed over the study period (P= 0.625). Two
children receiving placebo reported abdominal pain or vomiting
and withdrew from the study.
DISCUSSION
Children supplemented with a combination of the Lab4 probiotic
consortium and vitamin C for 6 months attending preschool facilities
showed a reduced incidence and duration of URTI symptoms.
Studies with probiotics alone have shown variable results for URTIs,
with some reporting signiﬁcant reductions in incidence and
duration7–11 while others observed little or no effect.12,13 Positive
effects on URTI have been reported in response to Lactobacillus casei
DN-114 001, Lactobacillus rhamnosus GG and for Lactobacillus
acidophilus NCFM alone or in combination with Biﬁdobacterium
animalis sp lactis Bi-07 at doses ranging from 109 to 1010 colony-
forming units per day7–11 while limited evidence exists suggesting
that supplementation with low dose vitamin C (o0.2 g per day)
may reduce common cold duration (discussed by Hemila et al.14).
A probiotic consortium combined with multi-vitamins and minerals
in adults showed a 13.6% reduction in the incidence of combined
URTI and LRTI symptoms.18 There was no impact on LRTI or
gastrointestinal symptoms in this study although beneﬁts have been
reported elsewhere.7,8,19,20
Children receiving the Lab4/vitamin C combination had fewer
days of absence from preschool and unscheduled visits to the
paediatric physician, suggesting that combined supplementation
may reduce the severity of infections. Reductions in preschool
absence have been reported with probiotics8–10 and with a vitamin
C (150mg per day), echinacea and propolis combination.20 Fewer
children receiving the supplement were treated with oral antibiotics
similar to that seen in other probiotic studies,8,10 and there was a
signiﬁcant reduction in the number of days that cough medicine
was used which highlights the potential socio-economic beneﬁts
associated with the combination supplement.
Metabonomics is a new approach providing a systematic
analysis of the chemical products or metabolites in biological
samples, such as urine, blood and faeces, and is considered as a
very sensitive measure of an organism’s phenotype.21 In this
study, no changes in the urinary metabolite proﬁles of healthy
preschool children were observed between the placebo and
active groups. The major metabolites identiﬁed in 1H NMR spectral
data agreed with those observed in healthy children.22
Both probiotics and vitamin C are known to modulate the
immune system,23,24 and the combination probably mediates a
response through immune-modulation although the absence of
any signiﬁcant changes in cytokines levels between the active and
placebo groups in our study may suggest the existence of an
alternate mechanism. Although there were no signiﬁcant differ-
ences in salivary IgA levels between the active group and placebo,
Cáceres et al.13 observed increased faecal IgA levels in Lacto-
bacillus rhamnosus HN001-supplemented children but was unable
to associate this with any improvements in URTI symptoms. The
trend towards a reduction in IL-2/IL-5 and IFN-γ levels may
suggest a shift towards an anti-inﬂammatory state in the
supplemented group, and this is consistent with the abilities of
both the Lab4 consortium and vitamin C to induce an anti-
inﬂammatory response in immune cells extracted from the blood
of healthy subjects.16,17
Table 3. Incidence rate of URTI symptoms and absence
PP analysis ITT analysis
Incidence rate ratio (95% CI) P-value Incidence rate ratio (95% CI) P-value
URTI symptoms 0.67 (0.52, 0.86) 0.002 0.68 (0.54, 0.86) 0.002
Individual URTI symptoms
Sneezing 0.29 (0.19, 0.47) o0.001 0.35 (0.23, 0.53) o0.001
Cough 0.55 (0.40, 0.76) o0.001 0.60 (0.45, 0.81) 0.001
Runny nose 0.64 (0.47, 0.87) 0.005 0.66 (0.50, 0.89) 0.005
Blocked nose 1.15 (0.69, 1.91) 0.600 1.01 (0.64, 1.59) 0.966
Sore throat 0.70 (0.39, 1.26) 0.235 0.63 (0.37, 1.08) 0.095
Absence
Absence from preschool 0.70 (0.55, 0.91) 0.007 0.68 (0.54, 0.87) 0.002
Abbreviations: CI, conﬁdence interval; ITT, intention to treat; PP, per protocol; URTI, upper respiratory tract infection.
Table 4. Duration and incidence of LRTI conﬁrmed by paediatric
physician
PP analysis ITT analysis
Placebo
(N=29)
Active
(N=28)
Placebo
(N=33)
Active
(N= 33)
Number of days
Mean (s.d.), days 1.0 (3.4) 0.5 (1.8) 0.9 (3.2) 0.9 (3.5)
Mean difference (95% CI) −0.6 (−2.0, 0.8) 0.03 (−1.6, 1.6)
P-value 0.425 0.970
Incidence rate ratio (95% CI) 0.5 (0.1, 2.8) 1.0 (0.2, 4.0)
P-value 0.447 0.989
Abbreviations: CI, conﬁdence interval; ITT, intention to treat; LRTI, lower
respiratory tract infection; PP, per protocol.
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Subgroup analysis of our population on the basis of gender
revealed reduced URTI symptoms in boys that corresponded with
reduced plasma levels of IL-12p70, IL-12p70/IL-10, IL-2/IL-10 and
IL-12/IL-5, indicating a more anti-inﬂammatory basal immune status.
Positive effects of both probiotics and vitamin C on RTIs have been
seen in adolescent and adult male subjects,25–27 and it is known that
X-chromosome-speciﬁc immune-modulatory genes mediate male-
speciﬁc immunological responses during prepubescence.28
As this was a pilot study with a small number of participants, it
was not powered to detect all statistically signiﬁcant differences,
and an unwillingness to provide blood or saliva reduced the
samples size for the secondary end point analysis. Also, the impact
of the intervention at the time of an infection was not evaluated in
this study.
CONCLUSIONS
Supplementation with a probiotic consortium comprising
L. acidophilus CUL21 and CUL60, Biﬁdobacterium biﬁdum CUL20,
Biﬁdobacterium animalis subsp. lactis CUL34 and vitamin C may
provide a strategy to reduce the incidence of URTIs in 3–6 year old
children attending preschool facilities. These results are encoura-
ging and need to be conﬁrmed in a larger study population.
CONFLICT OF INTEREST
The study was sponsored by Cultech Ltd, UK. IG, DRM and SFP are employees of
Cultech Ltd and had no role in the recruitment, data collection and analysis.
The remaining authors declare no conﬂict of interest.
b
a
d
c
Per Protocol (PP)
b
a
d
c
Intention to Treat (ITT)
7.07.58.08.5 ppm 1.01.52.02.53.03.54.04.5 ppm
7.07.58.08.5 ppm 1.01.52.02.53.03.54.04.5 ppm
7.07.58.08.5 ppm 1.01.52.02.53.03.54.04.5 ppm
7.07.58.08.5 ppm 1.01.52.02.53.03.54.04.5 ppm
D-3-hydroxybutyrate
Very diluted
Unknown singlets 
Acetaminophen  and its metabolites
Figure 2. The upper plots illustrated PCA scores plots derived from 1H NMR spectra of urinary samples collected from children at baseline
(black) and after 6 months intervention (grey) in per protocol (PP) analyses and intention to treat (ITT), respectively. Open triangles for girls
placebo group; closed triangles for girls active group; open circles for boys placebo group; closed circles boys active group. Six strong outliers
are observed, and their NMR spectra are shown in panels a–d. Outlier (a) contains a high concentration of D-3-hydroxybutyrate. Outlier (b) is
due to its extreme dilution of the sample. Outlier (c) shows a set of unknown singlets at 0.54, 0.43 and 1.62 p.p.m. Group (d) exhibit signals of
acetaminophen and its metabolites.
The PROCHILD study
I Garaiova et al
6
European Journal of Clinical Nutrition (2014) 1 – 7 © 2014 Macmillan Publishers Limited
ACKNOWLEDGEMENTS
We thank J Karácsony MD, P Lukács MD, G Miškejová MD, A Žemberová MD,
Ľ Chandogová, D Opalená, A Kissová, B Rásóová, K Farkasová, Ľ Zámečníková and
M Lengyelová for excellent clinical and technical assistance and all children
and parents who participated in the study.
AUTHOR CONTRIBUTIONS
IG and JM were responsible for study design, interpretation of data after
statistical analysis and manuscript writing; ZN was responsible for recruitment,
clinical assessment and data collection; JL was responsible for the metabolite
analysis, data interpretation and writing metabonomics sections; ZO contributed
to data collection; DRM contributed to interpretation of immunological data;
DW carried out statistical analysis; and SFP and ZĎ contributed to study design,
Ethical Committee documents and coordination of the study. All authors assisted
in reviewing the manuscript and approved the ﬁnal manuscript.
REFERENCES
1 Hollinghurst S, Gorst C, Fahey T, Hay AD. Measuring the ﬁnancial burden of acute
cough in pre-school children: a cost of illness study. BMC Fam Pract 2008; 9: 10.
2 Dales RE, Cakmak S, Brand K, Judek S. Respiratory illness in children attending
daycare. Pediatr Pulmonol 2004; 38: 64–69.
3 Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the
prevention of respiratory tract infections: a systematic review. Int J Antimicrob
Agents 2009; 343: e191–110.
4 Ballengee CR, Turner RB. Supportive treatment for children with the
common cold. Curr Opin Pediatr 2014; 26: 114–118.
5 Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper
respiratory tract infections. Cochrane Database Syst Rev 2011; 9: CD006895.
6 FAO/WHO. Report of a Joint FAO/WHO Expert Consultation on evaluation of health
and nutritional properties of probiotics in food including powder milk with live lactic
acid. Food and Agriculture Organization of the United Nations/World Health
Organisation: Cordoba, Argentina. Available at: ftp://ftp.fao.org/docrep/fao/009/
a0512e/a0512e00.pdf. 2001.
7 Merenstein D, Murphy M, Fokar A, Hernandez RK, Park H, Nsouli H et al. Use of a
fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to
decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-
blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr 2010;
64: 669–677.
8 Hatakka K, Savilahti E, Pönkä A, Meurman JH, Poussa T, Näse L et al. Effect of long
term consumption of probiotic milk on infections in children attending day care
centres: double blind, randomised trial. BMJ 2001; 322: 1327.
9 Hojsak I, Snovak N, Abdović S, Szajewska H, Misak Z, Kolacek S. Lactobacillus GG in
the prevention of gastrointestinal and respiratory tract infections in children who
attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin
Nutr 2010; 29: 312–316.
10 Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and
inﬂuenza-like symptom incidence and duration in children. Pediatrics 2009; 124:
e172–e179.
11 Kumpu M, Lehtoranta L, Roivainen M, Rönkkö E, Ziegler T, Söderlund-Venermo M
et al. The use of the probiotic Lactobacillus rhamnosus GG and viral ﬁndings in the
nasopharynx of children attending day care. J Med Virol 2013; 85: 1632–1638.
12 Agustina R, Kok FJ, van de Rest O, Fahmida U, Firmansyah A, Lukito W et al.
Randomized trial of probiotics and calcium on diarrhea and respiratory tract
infections in Indonesian children. Pediatrics 2012; 129: e1155–e1164.
13 Caceres P, Montes S, Vega N, Cruchet S, Brunser O, Gotteland M. Effects of
Lactobacillus rhamnosus HN001on acute respiratory infections and intestinal
secretory IgA in children. J Pediatr Infect Dis 2010; 5: 9.
14 Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold.
Cochrane Database Syst Rev 2013; 1: CD000980.
15 Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB
et al. Lactobacillus-mediated priming of the respiratory mucosa protects against
lethal pneumovirus infection. J Immunol 2011; 186: 1151–1161.
16 Hepburn NJ, Garaiova I, Williams EA, Michael DR, Plummer S. Probiotic
supplement consumption alters cytokine production from peripheral blood
mononuclear cells: a preliminary study using healthy individuals. Benef Microbes
2013; 4: 313–317.
17 Härtel C, Strunk T, Bucsky P, Schultz C. Effects of vitamin C on intracytoplasmic
cytokine production in human whole blood monocytes and lymphocytes.
Cytokine 2004; 27(4-5), 101–106.
18 Winkler P, de Vrese M, Laue C, Schrezenmeir J. Effect of a dietary supplement
containing probiotic bacteria plus vitamins and minerals on common cold
infections and cellular immune parameters. Int J Clin Pharmacol Ther 2005; 43:
318–326.
19 Lin JS, Chiu YH, Lin NT, Chu CH, Huang KC, Liao KW et al. Different effects of
probiotic species/strains on infections in preschool children: a double-blind,
randomized, controlled study. Vaccine 2009; 27: 1073–1079.
20 Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y. Effectiveness of an
herbal preparation containing echinacea, propolis, and vitamin C in
preventing respiratory tract infections in children: a randomized, double-blind,
placebo-controlled, multicenter study. Arch Pediatr Adolesc Med 2004; 158:
217–221.
21 Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C et al. The human urine
metabolome. PLoS One 2013; 8: e73076.
22 Gu H, Pan Z, Xi B, Hainline BE, Shanaiah N, Asiago V et al. 1H NMR me study of age
proﬁling in children. NMR Biomed 2009; 22: 826–833.
23 Johnson CL, Versalovic J. The human microbiome and its potential importance to
pediatrics. Pediatrics 2012; 129: 950–960.
24 Maggini S, Wenzlaff S, Hornig D. Essential role of vitamin C and zinc in child
immunity and health. J Int Med Res 2010; 38: 386–414.
25 West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A et al.
Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and
respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J
2011; 10: 30.
26 Baird IM, Hughes RE, Wilson HK, Davies JE, Howard AN. The effects of ascorbic
acid and ﬂavonoids on the occurrence of symptoms normally associated with the
common cold. Am J Clin Nutr 1979; 32: 1686–1690.
27 Constantini NW, Dubnov-Raz G, Eyal BB, Berry EM, Cohen AH, Hemilä H. The effect
of vitamin C on upper respiratory infections in adolescent swimmers: a
randomized trial. Eur J Pediatr 2011; 170: 59–63.
28 Casimir GJ, Heldenbergh F, Hanssens L, Mulier S, Heinrichs C, Lefevre N et al.
Gender differences and inﬂammation: an in vitro model of blood cells stimulation
in prepubescent children. J Inﬂamm (Lond) 2010; 7: 28.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/
Supplementary Information accompanies this paper on European Journal of Clinical Nutrition website (http://www.nature.com/ejcn)
The PROCHILD study
I Garaiova et al
7
© 2014 Macmillan Publishers Limited European Journal of Clinical Nutrition (2014) 1 – 7
